Anika Therapeutics Inc (ANIK) is a publicly traded Healthcare sector company. As of May 21, 2026, ANIK trades at $15.50 with a market cap of $198.92M and a P/E ratio of -19.92. ANIK moved +1.48% today. Year to date, ANIK is +59.87%; over the trailing twelve months it is +26.59%. Its 52-week range spans $7.87 to $25.65. Analyst consensus is buy with an average price target of $17.50. Rallies surfaces ANIK's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Hedge funds tracked by Rallies that own ANIK include Exoduspoint Capital. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Anika Therapeutics Inc.
| Metric | Value |
|---|---|
| Price | $15.50 |
| Market Cap | $198.92M |
| P/E Ratio | -19.92 |
| EPS | $-0.76 |
| Dividend Yield | 0.00% |
| 52-Week High | $25.65 |
| 52-Week Low | $7.87 |
| Volume | 10 |
| Avg Volume | 0 |
| Revenue (TTM) | $112.82M |
| Net Income | $-10.88M |
| Gross Margin | 56.56% |
2 analysts cover ANIK: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $17.50.